You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Copy file name to clipboardExpand all lines: index.Rmd
-68Lines changed: 0 additions & 68 deletions
Original file line number
Diff line number
Diff line change
@@ -580,71 +580,3 @@ test or use this data to advance their own work. This would lead to substantial
580
580
scientific and medical advancements, which will ultimately lead to
581
581
individualised treatment and improved human health in individuals with type 2
582
582
diabetes, and very likely the population overall.
583
-
584
-
# References
585
-
586
-
# Questions to discuss (before or after submission)
587
-
588
-
1. What is DD2's current Research Data Management Plan?
589
-
3. Thoughts on converting this into an
590
-
article/implementation piece? It’s a fair amount of work we’ve put into it and
591
-
(I believe) would have a considerable benefit to publishing and having people
592
-
read about it.
593
-
6. When we get funding, how to limit new personnel from the
594
-
struggles of dealing with the Region’s IT setup? And not have them be given a
595
-
Region computer, which will *for sure* reduce their productivity.
596
-
597
-
# TODO
598
-
599
-
## After submission
600
-
601
-
- TODO: Will eventually need to build a more detailed use case description.
602
-
- IDEA: Some way of generating a DOI for the DD2 itself/for the underlying database, without actually making the data public? Maybe the code or framework, along with the version? Need people to cite it somehow.
603
-
- IDEA: Use this as the basis for a paper on the implementation details of the framework, to show we’re serious about it, and as a way to make this proposal itself a scientific output.
604
-
- TODO: Reference to Data Package/Frictionless Data as Common Data Model: [https://frictionlessdata.io/](https://frictionlessdata.io/) ? Need to decide on exact Data Model.
605
-
- TODO: Basic overview of strengths and weaknesses?
606
-
- TODO: Add notes about licensing and copyright. For software, usually copyright resides with the employer (e.g. for SDCA that would be Region Midt). We’d need to discuss this with the employer before we can move too much forward. License should be permissible, e.g. by using MIT License.
607
-
- TODO: Will need to include a list of “prerequisites” that potential users of this framework would need access to (or similar enough free resources) in order to either minimally or optimally make use the framework
608
-
609
-
# Misc useful information
610
-
611
-
- Access to data through “forskermaskine” requires a valid authorization, usually given to only one person (often the head of department) per approved institution. Importantly, if even one researcher working under the institution's authorization breaches data confidentiality (through transferring microdata outside the “forskermaskine”), the access is closed for the entire institution, and in the worst case permanently. Therefore, the authorized institutions (and corresponding persons) are reluctant to give access to researchers outside their own institutions or close collaborators. Thus, DD2 is presently working on establishing legal procedures for data access for researchers from different institutions (national and international).
612
-
- File size of SNP/Genotyping/GWAS data: 0.000072MB per SNP per individual. So for 6,000 individuals and 1 mio genotyped SNPs: 0.4 TB. Also, approx 20 mio SNPs will probably be imputed, so times that by 20, and you get about 8 TB. This is for the planned GWAS 2. GWAS 1 is already available (first 3,000 participants and 500,000 genotyped SNPs, several mio. imputed) is maybe half that size, or smaller, so approx. additional 2-4 TB. Some references [here](https://www.ncbi.nlm.nih.gov/pubmed/29734293) and [here](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795954/).
0 commit comments